Summary
On the 14th November 2024, Prostate Cancer Research launched their cost benefit analysis report at the Houses of Parliament with the support of Rt Hon. James Cleverly MP, Rt Hon. David Lammy MP, Josh Rt Hon. James Cleverly MP, Rt Hon. David Lammy MP, Josh Babarinde MP, PCR CEO Oliver Kemp and Sir Steve McQueen.
This report from Prostate Cancer Research looks at the benefits of screening for prostate cancer in the UK. Prostate cancer is the most common cancer in men, with Black men and those in poorer areas at higher risk. Many cases are diagnosed late, reducing chances of survival. The study suggests that targeted screening for high-risk groups could save lives and reduce healthcare costs. Current tests, like the PSA test, have limits, such as false results, but new tools like AI and advanced blood tests could improve accuracy and avoid unnecessary treatments.
Introducing a screening program could bring over £200 million in benefits and save thousands of lives by catching cancer earlier. It would also ease the strain on the healthcare system. To make this work, it’s important to focus on better tests and ensure groups most at risk can access screening. The report calls for action now, while continuing research to find the best solutions. Click here to read the full version.